

## AMENDMENTS TO THE CLAIMS

- 0 NOT  
ster  
his  
amendment.  
JD  
1/13/04
- 1-23. (Previously cancelled)
  - 24. (Currently canceled)
  - 25-27. (Previously canceled)
  - 28. (Currently canceled)
  - 29. (Previously canceled).
  - 30-36. (Currently canceled)
  - 37-39. (Previously canceled).
  - 40. (Currently canceled)
  - 41. (Previously canceled).
  - 42-43. (Currently canceled)
  - 44-45. (Previously canceled)
  - 46-49. (Currently canceled)

50. (New) A pharmaceutical composition for use in breast cancer therapy in humans, said composition comprising:

(a) at least one antineoplastic agent selected from the group consisting of epirubicin and docetaxel, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, or combination thereof; and

(b) aromatase inhibitor exemestane and a pharmaceutically acceptable carrier,  
pharmaceutically acceptable diluent, or combination thereof,

wherein said antineoplastic agent and said aromatase inhibitor are present in superadditive antitumor effective amounts.